CMPX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Compass Therapeutics Inc. (CMPX) is not a strong buy at this time for a beginner investor with a long-term focus. While there is potential upside in the long term due to positive analyst ratings and upcoming clinical data, the current technical indicators, lack of significant trading trends, and weak financial performance suggest that it is better to hold off on investing right now.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 46.983, showing no clear signal. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading below the pivot level of 6.509, with support at 6.25 and resistance at 6.769. The short-term trend indicates a potential decline of -2.62% in the next day and -5.94% in the next month.
Analysts have raised price targets, with Canaccord seeing potential upside to $13 based on upcoming Phase 2/3 clinical data. William Blair has an Outperform rating, citing the potential success of the company's lead program in biliary tract cancer.
No recent news or significant insider/hedge fund activity. Financials show weak performance with no revenue growth, negative net income (-$14.26M), and a gross margin of 0%. The stock has a high implied volatility (182.4%), indicating uncertainty.
In Q3 2025, revenue remained at $0 with no YoY growth. Net income improved by 36.05% YoY but remains negative at -$14.26M. EPS stayed flat at -0.08, and gross margin dropped to 0%. Overall, the financial performance is weak.
Analysts are optimistic with Buy and Outperform ratings. Canaccord raised the price target to $13, citing manageable safety and statistically significant benefits from clinical trials. William Blair sees potential success in the company's lead program but has not provided a price target.
